Comparative Pharmacology
Head-to-head clinical analysis: DISPERMOX versus UTICILLIN VK.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DISPERMOX versus UTICILLIN VK.
DISPERMOX vs UTICILLIN VK
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amoxicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity and disrupting peptidoglycan cross-linking.
Uticillin VK (penicillin V potassium) is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs) in the bacterial cytoplasmic membrane, thereby inhibiting transpeptidation and autolysin inhibition, leading to cell lysis and death.
Adults: 1 g (as amoxicillin 875 mg + clavulanate 125 mg) orally every 12 hours for 7-10 days.
250-500 mg orally every 6-8 hours for 10 days for streptococcal pharyngitis; 250-500 mg orally every 6 hours for pneumococcal infections.
None Documented
None Documented
Terminal elimination half-life 1.5 hours; prolonged in renal impairment.
0.5-1.0 hour (prolonged in renal impairment; e.g., up to 10 hours in anuria)
Renal excretion 80% as unchanged drug, biliary/fecal 10%.
Renal: 70-80% unchanged via tubular secretion and glomerular filtration; biliary/fecal: minor (about 10%)
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic